Published in Cancer Weekly, August 21st, 2001
The primary analysis for this Phase II, multicenter, double-blind, placebo-controlled trial was designed to compare time to disease relapse in patients who demonstrate an immune response to OvaRex monoclonal antibody (MAb) versus patients who do not. Importantly, results from the trial provide, for the first time, validated quality-of-life data associated with the administration of OvaRex MAb as compared with placebo.
The trial, with Dr. Michael Bookman of the Fox...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.